Management of mild systemic lupus erythematosus

Hong Kong Practitioner

Volumn 24, Issue 1, 2002, Pages 34-39

  Chau, S Y ^a   Mok, C C ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DAPSONE; DIURETIC AGENT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; RETINOID; ROFECOXIB; STEROID; THALIDOMIDE;

AGRANULOCYTOSIS; ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; EYE DISEASE; FIBROMYALGIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MYOPATHY; PEPTIC ULCER; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; PROGNOSIS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA; VERTIGO;

EID: 0036146701     PISSN: 10273948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Late onset systemic lupus erythematosus in southern Chinese
2. Clinical profile of patients with late-onset SLE: Not a benign subgroup
3. An overview of systemic lupus erythematosus in Hong Kong. Part 1: Clinical manifestations and immunogenetics
4. Management strategy for systemic lupus erythematosus
5. Acute transverse myelopathy in systemic lupus erythematosus: Clinical presentation, treatment and outcome
6. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens
7. Management of osteonecrosis in systemic lupus erythematosus
8. Risk factors for avascular bone necrosis in systemic lupus erythematosus
9. Risk factors for osteonecrosis in systemic lupus erythematosus
10. Avascular necrosis in systemic lupus erythematosus: Clinical associations and a 47-year perspective
11. Bilateral Kienbock's disease in SLE
12. Kienbock's disease in rheumatoid arthritis
13. Multiple osteonecrotic lesions in systemic lupus erythematosus
14. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus
15. The musculoskeletal system
16. Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases
17. Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomised controlled trial
18. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
19. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional non-steroidal anti-inflammatory drugs
20. Core decompression with bone grafting for osteonecrosis of the femoral head
21. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus
22. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: A critical review
23. Antimalarial therapy: A panacea for mild lupus?
24. Antimalarial agents and lupus
25. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine
26. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus
27. The efficacy of antimalarials in systemic lupus erythematosus
28. A randomised study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
29. Royal College of Ophthalmologists guidelines: Ocular toxicity and hydroxychloroquine
30. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice
31. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic
32. Guidelines for monitoring drug therapy in rheumatoid arthritis